Search

everythinglearnresearchcommunity

for

Search:↓

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.

Some off-label treatments may be effective for male pattern baldness.

Clinicians should use social and prescription data to track trends in performance-enhancing drug use.

Effective treatments for discoid lupus erythematosus are needed, as current options are unsatisfactory and off-label.

Off-label treatments are heavily used for alopecia areata due to limited approved options.

The document concludes that doctors should carefully consider off-label drug use in dermatology and always inform patients, while more research is needed on the safety and effectiveness of such practices.

Biologics and JAK inhibitors may improve treatment for scarring alopecias.

Most off-label drug prescriptions in Saudi Arabia are for adults with depression and diabetes.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

Emerging injectable treatments like PRP, stem cells, and exosomes show promise for safer, more effective hair growth.

Treating alopecia areata is difficult due to limited approved treatments, but new therapies like JAK inhibitors show promise.

Children with alopecia areata need supportive care and off-label treatments due to a lack of approved options.

Permanent hair loss from cicatricial alopecia is treated by reducing inflammation and managing symptoms, but regrowth in scarred areas is unlikely.

A new treatment plan helps manage folliculitis decalvans effectively.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

Testosterone therapy can modestly improve sexual function in menopausal women but should be used cautiously and is not recommended for routine measurement in sexual dysfunction or hirsutism.

The Drug Ontology was updated to better classify drugs for hypertension, malaria, and opioid abuse, and to allow for more accurate research queries.

New treatments for male pattern hair loss look promising, but established treatments are still the main option.

Spironolactone does not increase the risk of breast cancer recurrence.

The document concludes that treatments for female hair loss and excess body hair are available, but managing expectations is important.

The document concludes that there are various treatments for different types of alopecia, but more research is needed for evidence-based treatments.

Hormone treatments can help with women's skin and hair disorders, but they need careful monitoring and more research.

Two drugs, finasteride and minoxidil, are approved for hair loss treatment, but new therapies are being developed.

Alopecia areata in Saudi Arabia is costly, mainly due to lost productivity and drug costs.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Topical corticosteroids are the preferred first treatment for children with Alopecia Areata.

Minoxidil and finasteride are FDA-approved treatments for male hair loss, but off-label use of oral minoxidil, dutasteride, and higher doses of finasteride and minoxidil is increasing.

Control inflammation and prevent further hair loss in folliculitis decalvans using medications and therapies.

Onabotulinumtoxin-A effectively treated a painful scalp condition when other treatments failed.

Low-dose oral minoxidil is being revisited as a promising hair loss treatment.